{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:28:30Z","timestamp":1790911710610,"version":"4.1.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Melioidosis, an infection due to\n            <jats:italic>Burkholderia pseudomallei<\/jats:italic>\n            , is endemic in southeast Asia and northern Australia. We reviewed our experience with meropenem in the treatment of severe melioidosis in 63 patients over a 6-year period. Outcomes were similar to those of ceftazidime-treated patients (\n            <jats:italic>n<\/jats:italic>\n            = 153) despite a deliberate selection bias to more-unwell patients receiving meropenem. The mortality among meropenem-treated patients was 19%. One patient had a possible drug fever associated with the use of meropenem. We conclude that meropenem (1 g or 25 mg\/kg every 8 h intravenously for \u226514 days) is an alternative to ceftazidime and imipenem in the treatment of melioidosis. The use of meropenem may be associated with improved outcomes in patients with severe sepsis associated with melioidosis.\n          <\/jats:p>","DOI":"10.1128\/aac.48.5.1763-1765.2004","type":"journal-article","created":{"date-parts":[[2004,4,22]],"date-time":"2004-04-22T19:58:16Z","timestamp":1082663896000},"page":"1763-1765","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":87,"title":["Outcomes of Patients with Melioidosis Treated with Meropenem"],"prefix":"10.1128","volume":"48","author":[{"given":"Allen C.","family":"Cheng","sequence":"first","affiliation":[{"name":"Menzies School of Health Research, Charles Darwin University, Casuarina NT 0811, Northern Territory"},{"name":"Northern Territory Clinical School, Flinders University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale A.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Northern Territory Clinical School, Flinders University"},{"name":"Division of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M.","family":"Anstey","sequence":"additional","affiliation":[{"name":"Menzies School of Health Research, Charles Darwin University, Casuarina NT 0811, Northern Territory"},{"name":"Northern Territory Clinical School, Flinders University"},{"name":"Division of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne P.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Northern Territory Clinical School, Flinders University"},{"name":"Intensive Care Unit, Royal Darwin Hospital, Tiwi 0810, Darwin, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan P.","family":"Jacups","sequence":"additional","affiliation":[{"name":"Menzies School of Health Research, Charles Darwin University, Casuarina NT 0811, Northern Territory"},{"name":"Northern Territory Clinical School, Flinders University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J.","family":"Currie","sequence":"additional","affiliation":[{"name":"Menzies School of Health Research, Charles Darwin University, Casuarina NT 0811, Northern Territory"},{"name":"Northern Territory Clinical School, Flinders University"},{"name":"Division of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199206000-00025"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.7.862"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199912000-00001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/380456"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/318116"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200003000-00005"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1984.33.467"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0703.017310"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2001.65.76"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00334-4"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(92)90191-E"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010307"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.4.1676-1677.2001"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/315306"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/520219"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.3.611"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/33.1.145","volume":"33","year":"1994","unstructured":"Smith, M. D., V. Wuthiekanun, A. L. Walsh, and N. J. White. 1994. Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotics and antibiotic combinations using time-kill studies. J. Antimicrob. Chemother.33:145-149.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1445-5994.2002.00195.x","volume":"32","year":"2002","unstructured":"Stephens, D. P., D. A. Fisher, and B. J. Currie. 2002. An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern. Med. J.32:143-148.","journal-title":"Intern. Med. J."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.10.2356"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13374-0"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90768-X"},{"key":"e_1_3_2_23_2","unstructured":"Writing Group. 2003. Therapeutic guidelines: antibiotic 12th ed. Therapeutic Guidelines Ltd. North Melbourne Australia."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.10.2027"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.5.1763-1765.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.5.1763-1765.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:18:00Z","timestamp":1645467480000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.5.1763-1765.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1128\/AAC.48.5.1763-1765.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.5.1763-1765.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5]]},"assertion":[{"value":"2003-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-02-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}